Twelve-Month Treatment of Overactive Bladder
Tóm tắt
Context: Tolterodine is a bladder-selective antimuscarinic agent designed for the treatment of overactive bladder. Traditional antimuscarinic therapies are poorly tolerated due to a high incidence of anticholinergic adverse events and consequently few patients remain on long term therapy.
Objective: To evaluate the long term efficacy and tolerability of tolterodine in patients with symptoms of overactive bladder.
Design: Twelve-month open-label extension of 4 randomised, placebo-controlled, double-blind, multinational, multicentre trials of 4 weeks’ duration.
Patients: 714 patients (aged 18 to 92 years) with symptoms of overactive bladder who completed the double-blind portion of the studies.
Intervention: Tolterodine 2mg twice daily for up to 12 months.
Main outcome measures: Micturition diary variables: number of micturitions per 24 hours, number of urge incontinence episodes per 24 hours, mean urine volume voided per micturition. Safety variables: adverse events, study discontinuation rate.
Results: A total of 441 patients (62%) completed 12 months’ open-label treatment with tolterodine, which significantly reduced the number of micturitions per 24 hours [mean change −2.4, 95% confidence interval (CI) −2.7 to −2.2, median change −20%, p < 0.0001] and number of urge incontinence episodes per 24 hours (mean change −1.3, 95% CI −1.6 to −1.0, median change −74%, p < 0.0001), while the mean volume voided per micturition was significantly increased (+33ml, 95% CI +28 to +38, median change +18%; p < 0.0001). 41% of patients reported dry mouth (27% mild, 10% moderate, 3% severe). Dosage reduction to 1mg twice daily was required in 23% of patients. 15% of patients withdrew from the study due to adverse events, with 5% having associated dry mouth.
Conclusions: The high percentage of patients completing 12 months’ treatment indicates that tolterodine is an effective and well tolerated agent for long term treatment of overactive bladder.
Tài liệu tham khảo
Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how do we manage them? A population-based prevalence study. BJU Int 2001; 87: 760–6
Jackson S, Haab F, Larsson G, et al. The prevalence of the overactive bladder [abstract]. 28th Annual Meeting of the International Continence Society; 1998 Sep 14–7; Jerusalem
Ashworth PD, Hagan M. The meaning of incontinence: a qualitative study of non-geriatric urinary incontinence sufferers. J Adv Nurs 1993; 18: 1415–23
Fonda D, Woodward M, D’Astoli M, et al. Sustained improvement of subjective quality of life in older community dwelling people after treatment of urinary incontinence. Age Ageing 1995; 24: 283–6
Kelleher CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol 1995; 7: 404–8
Johannesson M, O’Connor RM, Kobelt G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 557–62
Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999; 83: 583–90
Frewen W. Role of bladder retraining in the treatment of unstable bladder in the female. Urol Clin North Am 1979; 6: 273–7
Oldenburg B, Millard RJ. Predictors of long term outcome following a bladder re-training programme. J Psychosom Res 1986; 30: 691–8
Andersson K-E. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477–94
Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988; 140: 47–50
Thüroff JD, Bunke B, Ebner A, et al. Randomized, doubleblind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813–7
Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243–62
Appell RA. Oxybutynin: the clinical experience. Contemp Urol 1991; 3: 60–4
Kelleher CJ, Cardozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988–93
Nilvebrant L, Andersson K-E, Gillberg P-G, et al. Tolterodine: a new bladder selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195–207
Nilvebrant L, Gillberg P-G, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 8: 169–72
Nilvebrant L, Hallén B, Larsson G. Tolterodine: a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129–36
Stahl MMS, Eckström B, Sparf A, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14: 647–55
Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997: 50Suppl. 6A: 90–6
Van Kerrebroeck PhEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478–9
Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801–10
Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999; 53: 990–8
Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551–5
Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283–9
Appell RA, Abrams P, Drutz H, et al. Treatment of overactive bladder; long term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141–7
Jacquetin B, Wyndaele J-J. Tolterodine reduced the number of incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reproductive Biol. In press
Jonas U, Höfner K, Madersbacher H, et al, and the participants of the international study group. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence and urgency: urodynamic evaluation. World J Urol 1997; 15: 144–51
Malone-Lee J, Walsh JB, Maugourd M-F, and the Tolterodine in the Elderly Study Group. Tolterodine: a safe and effective treatment for elderly patients with overactive bladder. J Am Geriatr Soc. In press
Herschorn S, Landy L, on behalf of the Tolterodine Study Group. ‘Cure’ rates for symptoms of overactive bladder treated with tolterodine [abstract 214]. 30th International Continence SocietyMeeting; 2000 Aug 28–31; Tampere, Finland
Aitchison MA, Carter R, Paterson P, et al. Is the treatment of urgency incontinence a placebo response? Results of a five year follow up. Br J Urol 1989; 64: 478–80
Labasky R, Leach G, Antoci J. Long-term experience with once-a-day extended-release oxybutynin in a community-based population treated for overactive bladder [abstract]. 29th International Continence Society Meeting; 1999 Aug 22–6; Denver (CO)